Down 5% so far this week, is the CSL share price a buying opportunity?

CSL shares have nosedived this week.

| More on:
A sad looking scientist sitting and upset about a share price fall.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is down 1.5% at $260 per share in afternoon trade on Wednesday. It has slipped 5% this week, having fallen from $271 at Friday's market close price.

Meanwhile, the S&P/ASX 200 Health Care Index (ASX: XHJ) has fallen 3% in the same time. The correlation between the two is seen below.

TradingView Chart

CSL standout healthcare pick: fund manager

CSL's management in particular impresses Sage Capital fund manager Sean Fenton. He said that whilst there are plenty of great Aussie healthcare companies available, CSL is his pick.

"Healthcare is really tough, in the sense that there's actually a whole bunch of really great Australian companies that have been very successful in healthcare," he said, speaking to Livewire's Buy Hold Sell.

"[I]t's hard to go past the biggest one, CSL, who have grown, exceptionally, in their area," he told Livewire.

The fund manager went on to comment on several of CSL's feats over the years. He noted its business strategy successfully diversified away from IVIG and haemophilia products into niche categories.

That's led to "a lot of value add" to the CSL share price he said.

And they continue to do that. Continue to reinvest, grow their market. Yeah. Their recent acquisition hasn't completed, Vifor, I think, will also prove to be quite an effective one. So, yeah. Really hard to go past them.

Analysts appear constructive too according to the data. Around 87% of brokers say it's a buy, with the remaining 13% presently saying it's a hold, according to Bloomberg data.

In the last 12 months, the CSL share price has slipped 13% into the red, or 10% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

1 ASX stock to consider buying that could be the next ResMed

There are obviously no guarantees in the share market. But if you're willing to take on some risk, the rewards…

Read more »

A couple stares at the tv in shock, one holding the remote up ready to press.
Healthcare Shares

Why this ASX biotech stock could rise a massive 40%

Bell Potter sees big returns on the cards for investors from this speculative stock.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords share is surging 16% after announcing a new finance chief

Is this announcement the real reason for the rise?

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

GLP-1 obesity medicines do the opposite of what ResMed stock investors feared

Internal research from ResMed provides some surprising news for investors on the impact of GLP-1s.

Read more »

A young woman with her mouth open and her hands out showing surprise and delight as uranium share prices skyrocket
Healthcare Shares

Guess which ASX AI stock rocketed 170% on an AstraZeneca update

Investors are loving this company's announcement on Wednesday.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Guess which ASX All Ords company is being sued by shareholders over stock price losses

Some of this biotech's shareholders aren't happy with management.

Read more »